Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche Backs 2021 Views After 1Q Sales Fall Slightly

04/20/2021 | 11:39pm EDT

By Olivia Bugault

Roche Holding AG said Wednesday that sales slightly decreased in its first quarter, while it confirmed its outlook for the year.

The Swiss pharmaceutical major posted sales of 14.93 billion Swiss francs ($16.30 billion), down from CHF15.14 billion a year earlier. At constant exchange rate, sales increased 3%, it said.

An analysts' consensus provided by FactSet had sales at CHF15.01 billion.

Sales at its pharmaceuticals division--its largest business--fell to CHF10.6 billion from CHF12.26 billion, while it rose 55% at constant exchange rate at its diagnostic division, it said.

The decline in sales at its pharmaceuticals business is mainly because of the coronavirus pandemic and the competition of biosimilars, Roche said. "The impact of biosimilars on sales of the established cancer medicines MabThera/Rituxan, Avastin and Herceptin remained significant (combined sales reduction of CHF1.6 billion), especially in the U.S.," it said.

Roche confirmed its 2021 outlook that includes expected sales growth in the low-to-mid-single-digit range at constant exchange rates.

Write to Olivia Bugault at olivia.bugault@wsj.com

(END) Dow Jones Newswires

04-21-21 0139ET

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 1.46% 34063.36 Delayed Quote.11.97%
ROCHE HOLDING AG 0.77% 301.05 Delayed Quote.-2.57%
All news about ROCHE HOLDING AG
05/11PROTHENAá : Announces achievement of $60 million milestone from roche for first ..
AQ
05/11ROCHEá : To Disclose Updated Results On 19 Approved, Investigational Therapies F..
MT
05/11ROCHEá : to present data from one of the most comprehensive oncology portfolios ..
AQ
05/11PRESS RELEASEá : Roche to present data from one of -3-
DJ
05/11PRESS RELEASEá : Roche to present data from one of -2-
DJ
05/11PRESS RELEASEá : Roche to present data from one of the most comprehensive oncolo..
DJ
05/11GENENTECHá : to Present Data From One of the Most Comprehensive Oncology Portfol..
BU
05/10CHUGAI PHARMACEUTICALá : Discontinues Marketing of Photodynamic Diagnostic Agent..
AQ
05/09Eli Lilly signs deals to boost supply of COVID-19 treatment in India
RE
05/06Switzerland says U.S. stance on vaccine patent waiver leaves questions
RE
More news
Financials
Sales 2021 60 430 M 66 589 M 66 589 M
Net income 2021 14 600 M 16 088 M 16 088 M
Net cash 2021 4 301 M 4 739 M 4 739 M
P/E ratio 2021 17,9x
Yield 2021 3,12%
Capitalization 260 B 286 B 287 B
EV / Sales 2021 4,23x
EV / Sales 2022 4,04x
Nbr of Employees 101 465
Free-Float 83,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 354,31 CHF
Last Close Price 301,05 CHF
Spread / Highest target 45,5%
Spread / Average Target 17,7%
Spread / Lowest Target -3,67%
EPS Revisions
Managers and Directors
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG-2.57%286 340
JOHNSON & JOHNSON6.88%442 937
PFIZER, INC.6.90%221 397
ABBVIE INC.7.29%203 045
NOVARTIS AG-4.30%197 785
MERCK & CO., INC.-4.65%197 501